Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Other cardiovascular complications seen in GBS patients were Increased pro-BNP(26.04%), raised troponin T levels(3.12%), acute coronary syndrome(2.08%), heart failure(2.08%) and abnormal 2D echo findings(8.33%).
|
31504947 |
2020 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Progressive aortic constriction in growing pigs induces significant LV hypertrophy with cardiac fibrosis associated with left atrial dilation, raised filling pressures, and an ability to transition to overt HF with raised BNP without reduction in LVEF.
|
31851785 |
2020 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The comparison of prognosis⁻predictivity of a single measurement of plasma NT-pro BNP in different follow-up periods in acute HF patients has been less studied.
|
30871208 |
2019 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Echocardiography and the expression of BNP showed that rivaroxaban attenuated heart failure.
|
30867376 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure.
|
30912456 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The study included 46 patients with HF and implanted CRT-D. Levels of NT-pro BNP and cTnThs were assessed during a 12 month follow up.
|
31223080 |
2019 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Baseline rSO2 was lower in patients with heart failure (45.2±8.3 % vs. 54.1±7.8 %, p=0.006) and was significantly linked to higher red cell distribution width (RDW) (r=-0.53, p?0.001) and higher BNP level (r=-0.45, p=0.01).
|
31177793 |
2019 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Accompanying these effects, tadalafil treatment normalized BNP mRNA and prevented development of subjective signs of HF.
|
31043634 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score.
|
29359586 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curve (ROC) analysis found that area under the ROC (AUC) was 0.616 (95%CI = 0.511-0.721, P = 0.034) when BNP was used to predict post-AMI HF, whereas AUC improved to 0.764 (95%CI = 0.674-0.855, P < 0.001) when miR-150 was used.
|
30745540 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
To develop a risk score to predict all-cause death for HFpEF patients, we examined 1277 HF patients with LVEF ≥50% and BNP ≥100 pg/ml in the CHART-2 Study, a large-scale prospective cohort study for HF in Japan.
|
30413304 |
2019 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The body weight, heart weight index (HWI), heart weight/tibia length ratio (HW/TL), and serum BNP level were investigated to assess the effect of LGZG on HF.
|
31829159 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
On multivariate analysis, admission initial stroke severity (OR 1.04, 95 CI% 1.004-1.07, p < 0.05) history of heart failure (OR 3.03, 95% CI 1.19-7.73, p < 0.05), ECG abnormalities and high BNP value (OR 4.34, 95% CI 2.59-7.29, p < 0.05) were associated with pure cardiac stroke mechanism.
|
29804788 |
2019 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Conclusions Analytical performances of the BNP and PBNP ADVIA methods are well in accordance with the quality specifications required by international guidelines for diagnosis and follow-up of patients with HF.
|
30412461 |
2019 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Patients with heart failure and CSA-CSR ± OSA have higher RRs but similar MV under ASV-therapy than patients with CSA and normal BNP.
|
29940592 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Atrial and brain natriuretic peptides (ANP and BNP) are established diagnostic and prognostic markers in heart failure, but their utility in patients with advanced cancer is unclear.
|
31128228 |
2019 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Following the recommendation of natriuretic peptides (B-type natriuretic peptide and N-terminal-proBNP), many other biomarkers have been thoroughly studied to reflect different pathophysiological processes (such as fibrosis, inflammation, myocardial injury, and remodeling) in HF and some of them (like cardiac troponins, soluble suppression of tumorigenesis-2, and galectin 3) have subsequently been recommended to aid in the diagnosis and prognostication in HF.
|
31183637 |
2019 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
For example, GWAS of NT-proBNP levels not only identified variants in the NNPA-NPPB locus but also substantiated data suggesting that natriuretic peptides in itself are associated with a lower risk of hypertension and HF.
|
29912321 |
2018 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
By multiple linear regression analysis adjusted for age and sex, heart failure (HF) and BNP strongly associated with sST2 concentration.
|
29428199 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Functionally, knockdown of BRD4 greatly downregulated the NPPA and NPPB in vivo and in vitro, improved the hemodynamic and biometric parameters in rat with heart failure, as well as decreased the apoptosis occurrence.
|
29352508 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac biomarkers troponin and brain natriuretic peptide/N-terminal proBNP (BNP/NT-proBNP) have been extensively studied in heart failure and acute coronary syndromes.
|
30701097 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure.
|
29959987 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.
|
29314505 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recommended cutoffs for BNP and NT-proBNP for ruling in and out HF were used for assessing diagnostic concordance and correlation.
|
30111510 |
2018 |
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure.
|
29959987 |
2018 |